# Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388(2) in Healthy Subjects

> **NCT05189288** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 65 (actual)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** D418 Tab.
- **DRUG:** CKD-388 Tab.

## Key facts

- **NCT ID:** NCT05189288
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-14
- **Primary completion:** 2022-03-12
- **Final completion:** 2022-04-15
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2022-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05189288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05189288, "Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388(2) in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05189288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*